Literature DB >> 23726875

Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus.

Alessio Aghemo1, Massimo Colombo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23726875     DOI： 10.1053/j.gastro.2013.05.028

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  3 in total

1.  Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.

Authors:  Jung Hwan Yu; Jung Il Lee; Kwan Sik Lee; Ja Kyung Kim
Journal:  Virol J       Date:  2017-08-24       Impact factor: 4.099

Review 2.  Hepatitis C virus NS5A inhibitors and drug resistance mutations.

Authors:  Shingo Nakamoto; Tatsuo Kanda; Shuang Wu; Hiroshi Shirasawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Authors:  James J Kohler; James H Nettles; Franck Amblard; Selwyn J Hurwitz; Leda Bassit; Richard A Stanton; Maryam Ehteshami; Raymond F Schinazi
Journal:  Infect Drug Resist       Date:  2014-03-05       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.